PicnicHealth
Aggregates patient medical records with consent to build research-ready data cohorts for pharma.
On the record
Checkpoint: New priced funding round or ThumbPrint contract wins among top-20 pharma sponsors
The call
PicnicHealth still holds real pharma relationships and patient data access, but 49 months without new funding and shrinking headcount show a company under financial strain while Datavant expands fast.
PicnicHealth gathers medical records directly from patients and sells that data to pharmaceutical companies like Roche to help them run drug studies and track real-world outcomes. The company built real relationships with large pharma over many years, but a much bigger rival called Datavant just bought two competitors (Aetion and DigitalOwl in mid-2025) and is now offering almost the same services. At the same time, PicnicHealth has not raised new funding in over four years, cut its staff by roughly one-quarter since 2024, and reports on revenue numbers that vary wildly (somewhere between $14.7 million and $61 million), suggesting the business is not growing clearly or fast. The one thing that matters most: whether PicnicHealth can sign up the biggest pharmaceutical companies as loyal customers in the next couple of quarters, which would prove that pharma companies prefer its approach of getting direct patient permission over what competitors are building.
Why
01
AI pressure: General-purpose LLMs (e.g., GPT-5 class models) doing medical record extraction. Large language models can now pull structured data from messy clinical notes, threatening to commoditize PicnicHealth's core extraction pipeline. Could AI do the core job? Only partly.
02
Bigger players: Datavant (post-Aetion/DigitalOwl acquisitions). Datavant, with $800M to $1B in revenue, bought Aetion and DigitalOwl in 2025 to build overlapping data-extraction and analytics tools at far larger scale. Could a giant copy it? Probably.
03
What protects it. Direct patient consent relationships and embedded pharma contracts, like the Roche/Genentech tie since 2018, give it data access rivals can't easily copy.
What would change this call
PicnicHealth announces a new priced funding round in the next 6-12 months. Would show whether investors still value the company after 49 months without a raise.
A top-20 pharma sponsor (e.g. Roche, AstraZeneca, Novartis) shifts volume to Datavant or Truveta. Would show the patient-consent moat is eroding under competitive pressure.
ThumbPrint wins or loses adoption among top-20 pharma sponsors by late 2026. Would test whether patient-anchored evidence beats Datavant's tokenized approach.
A top-20 pharma sponsor (e.g. Roche, AstraZeneca, Novartis) shifts volume to Datavant or Truveta. Would show the patient-consent moat is eroding under competitive pressure.
ThumbPrint wins or loses adoption among top-20 pharma sponsors by late 2026. Would test whether patient-anchored evidence beats Datavant's tokenized approach.
Key numbers
- $60M Series C, last priced round
- Headcount fell 23%, 360 to 277 staff
- Revenue estimates span $14.7M to $61M
Named risks
- No priced funding round in 49 months as of July 2026, raising risk of a down round or distress M&A.
- Datavant's serial acquisitions (Aetion, DigitalOwl) directly encroach on PicnicHealth's AI-record-analysis niche.
- Headcount contracted about 23% from a 2024 peak of 360 to 277 by mid-2026.
- Third-party revenue estimates conflict wildly ($14.7M to $61.3M), no verified growth metric disclosed.
- CEO transition (Leviner to Federici, June 2026) coincides with unproven ThumbPrint launch and rebrand execution.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Datavant | gaining on | Acquired Aetion (Jul 2025) and DigitalOwl (Oct 2025), directly entering AI-driven RWE and record analysis |
| IQVIA | contesting | Dominant incumbent aggregating over 1.2B patient records globally as of mid-2026 |
| Truveta | contesting | Provider-owned consortium of 30+ health systems with 100M+ patients and direct EHR access |
| TriNetX | contesting | Federated network spanning 250M+ patients across health systems, alternative RWD sourcing model |
Questions people ask
- Is PicnicHealth profitable in 2026?
- No profitability figures have been disclosed. Third-party revenue estimates conflict widely, from $14.7M (Latka, 2024) to $61.3M (Growjo, 2022 estimate), and the company has not raised a priced round since its $60M Series C in June 2022, suggesting no confirmed breakout growth.
- Who is PicnicHealth's biggest competitor?
- Datavant is the most direct threat: it acquired Aetion (real-world-evidence analytics) in July 2025 and DigitalOwl (AI medical-record analysis) in October 2025, moving straight into PicnicHealth's AI record-analysis and RWE niche as a much larger, well-funded incumbent.
- Could AI replace PicnicHealth's business?
- AI is commoditizing the record-extraction layer PicnicHealth built its early edge on, but not the direct, consented patient relationships it maintains since 2014. PicnicHealth itself launched PicnicAI (June 2024) and an AI health assistant (November 2024) to lean into this shift.
- Who owns PicnicHealth and how much funding has it raised?
- PicnicHealth is privately held and VC-backed, founded January 2014 by Noga Leviner and Troy Astorino. Disclosed priced rounds total about $97M: $2M seed (2015), $10M Series A (2018), $25M Series B (Sept 2020), and $60M Series C (June 27, 2022).
- Did PicnicHealth change its name?
- Yes. In April 2026 the company rebranded its parent entity as PicnicAI, splitting into PicnicHealth (patient-facing) and PicnicResearch (sponsor-facing) sub-brands, announced April 28, 2026 via PR Newswire.
- Is Roche/Genentech still working with PicnicHealth?
- Yes, the relationship has run since 2018 and was expanded in April 2023 to cover neurological disease research including MS, Huntington's, Alzheimer's, and myasthenia gravis, per a PicnicHealth announcement dated April 23, 2023.
Timeline
- 2026-06-23Noga Leviner steps to board; COO Luna Federici becomes CEO
- 2026-04-28Corporate rebrand to PicnicAI with PicnicHealth/PicnicResearch sub-brands
- 2026-03-26Launched ThumbPrint, patient-anchored alternative to tokenization
- 2025-10Datavant acquires DigitalOwl, an AI medical-record analysis firm
- 2025-07-15Neurocrine Biosciences collaboration on CAHtalog rare-disease registry
- 2025-07Datavant acquires Aetion, a real-world-evidence analytics company
- 2025-01-06Orsini and AstraZeneca partner with PicnicHealth on WAINUA hATTR-PN registry
- 2024-11-18Launched Picnic, an AI health assistant for patients
- 2024-06Launched PicnicAI generative-AI research platform
- 2023-10-23Acquired AllStripes, a rare-disease evidence-generation platform
Revision history
22 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Empowering Patients to Play A Role in Research With Real-World Evidence (2024-11-20)
- PicnicHealth Rebrands as PicnicAI, Building Intelligence to Accelerate Human Health (2026-04-28)
- PicnicHealth Stock Price, Funding, Valuation, Revenue & Financial Statements (2023-10-22)
- PicnicAI, Funding, Investors & Team (2026-07-09)
- PicnicHealth Announces $35M in Funding to Accelerate Medical Research Based on Real World Data (2020-09-01)
- PicnicHealth - Headcount, Funding & Open Jobs (2026-06-20)
- PicnicHealth picks up rare disease data collector AllStripes (2023-10-23)
- PicnicAI Names Luna Federici CEO to Lead Next Chapter of AI-Powered Health Research (2026-06-23)
- PicnicHealth - Overview, News & Similar companies (2026-07-06)
- PicnicHealth Revenue 2024 (2024-12-19)
- Revenue, Competitors, Alternatives (2022)
- Advancing Neuro Disease Research (2023-04-23)